TP53 and acute myeloid leukemia: Disappointingly, AML prognosis has not dramatically changed, even though the pharmacological armamentarium against AML has significantly increased over the last few years, currently including: (i) Classical chemotherapeutic agents: they are the mainstay of intensive therapy, but chemo-resistant clones are often selected, e.g., those harboring TP53 mutation or complex karyotypes.